Skyhawk Therapeutics publie les résultats à douze mois des sous-composantes de la cUHDRS issus de son essai clinique de phase 1/2 de SKY-0515 dans le traitement de la maladie de Huntington

Phase 2positiveSKY-0515Positive

AI Analysis

Summary

Skyhawk Therapeutics announced 12-month results from its Phase 1/2 trial of SKY-0515 for Huntington's disease, demonstrating favorable and consistent trends across multiple cUHDRS sub-components including functional capacity and motor scores.

Clinical Trial Data

Phase

1/2

Primary Endpoint

Met

Outcome Details

12-month results showed favorable and consistent trends across four cUHDRS sub-components including total functional capacity (TFC), total motor score (TMS), and digit symbol substitution test

Importance:6/10

Sentiment:

0.70

Huntington's diseaseSKY-0515Phase 1/2 trial12-month datacUHDRSpositive results

Read the original article

Published by PR Newswire Biotech on July 1, 2026 9:28 PM

Read Original